Compare ADPT & GEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | GEO |
|---|---|---|
| Founded | 2009 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2019 | 1994 |
| Metric | ADPT | GEO |
|---|---|---|
| Price | $18.46 | $18.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $16.60 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 515.49 |
| EPS | N/A | ★ 1.69 |
| Revenue | $252,754,000.00 | ★ $2,531,574,000.00 |
| Revenue This Year | $50.86 | $7.93 |
| Revenue Next Year | $0.53 | $15.02 |
| P/E Ratio | ★ N/A | $10.99 |
| Revenue Growth | ★ 42.57 | 4.43 |
| 52 Week Low | $6.26 | $14.27 |
| 52 Week High | $20.76 | $35.20 |
| Indicator | ADPT | GEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 68.70 |
| Support Level | $16.55 | $17.09 |
| Resistance Level | $19.16 | $18.30 |
| Average True Range (ATR) | 1.00 | 0.67 |
| MACD | 0.18 | 0.18 |
| Stochastic Oscillator | 82.08 | 92.68 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.